From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration of targeting “undruggable” KRAS mutations....
